We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.29 | 0.66% | 43.99 | 44.33 | 43.685 | 43.93 | 12,104,157 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Bristol-Myers Squibb Co. (BMY) said the European Commission approved a new indication for Revlimid, in combination with rituximab (anti-CD20 antibody), for adult patients with previously treated follicular lymphoma.
FL is a subtype of indolent, but incurable, non-Hodgkin lymphoma which is associated with immune system dysfunction.
The approval was based primarily on results from the phase 3 Augment study, which evaluated the combination versus rituximab plus placebo. In the study, treatment with the combination demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival, Bristol-Myers said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 20, 2019 07:32 ET (12:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
